Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
AROA BIOSURGERY LIMITED (ARX)ASX AI Signals has generated 2 signal(s) for ARX during the last 90 days, indicating Moderate trading activity
Latest ARX Signals | |
| 28/05/2026 | BUY |
| 10/04/2026 | SELL |
ARX Share Price | |
| Current Price | $0.570 |
| 52 Week High | $0.795 |
| 52 Week Low: | $0.510 |
| Trading at (% of 52 Week High) | 71.70% |
Aroa Biosurgery Limited (ASX: ARX) is a biotechnology company that develops and markets regenerative medicine products for surgical and wound care applications. The company focuses on bioactive materials derived from a patented extracellular matrix platform to help improve healing outcomes. Aroa serves medical professionals globally, particularly in wound care and soft tissue repair.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The BUY signal for AROA BIOSURGERY LIMITED (ARX) is supported by positive momentum and potential growth in the biosurgery sector. However, the relatively low stock price and sector volatility introduce moderate risk, warranting a cautious approach.
Aroa Biosurgery Limited (ASX:ARX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissu AUCKLAND, New Zealand, Nov. 29, 2022 /PRNewswire/ -- Today New Zealand based soft-tissue regeneration company Aroa Biosurgery (AROA, the Company) is pleased to announce financial results for H1 FY23. With fewer COVID-19 related disruptions, the Company has entered FY23 with momentum and delivered s AUCKLAND, New Zealand, Sept. 14, 2022 /PRNewswire/ -- New Zealand based soft tissue regeneration company Aroa Biosurgery (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr. Catherine Mohr as a Non-Executive Director to the board.
AROA's products are Over the last month the Aroa Biosurgery Limited (ASX:ARX) has been much stronger than before, rebounding by 32%. But that is minimal compensation for the share price under-performance over the last year. In fact, the price has declined 21% in a year, falling short of the returns you could get by inv Aroa Biosurgery Limited (ASX:ARX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissuLatest AROA BIOSURGERY LIMITED(ARX) News
Aroa Biosurgery Limited (ASX:ARX) Is Expected To Breakeven In The Near Future
AROA BIOSURGERY ANNOUNCES HALF YEAR RESULTS
DR CATHERINE MOHR TO JOIN BOARD OF MEDTECH COMPANY AROA BIOSURGERY
Shareholders in Aroa Biosurgery (ASX:ARX) are in the red if they invested a year ago
Breakeven On The Horizon For Aroa Biosurgery Limited (ASX:ARX)
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial